ANTHEMBSEANTHEM BIOSCIENCES LTD· Pharmaceuticals & BiotechnologyMediumNeutral
Announced Fri, 6 Nov, 2026 · 16:08 IST

Q2 FY27 revenue rises 8%, EBITDA margin reaches 50.6%

Management guided margin improvementOrder pipeline disclosedMulti-year targets disclosedInvestor Communications View source PDFExplain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+4.9%Reaction day
₹915.00
prior close
₹949.00
announcement price
After-mkt
timing
Nifty Midcap 150market+0.6%+4.3% vs market
Biotechnology peers, median of 5sector+0.1%+4.8% vs sector

On the reaction day the stock moved 4.3 pts more than Nifty Midcap 150 and 4.8 pts more than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+2.6
10m
+3.3
15m
+3.3
30m
+2.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+4.9+0.6+4.3+0.1+4.8
Next day
+4.7+1.5+3.2+0.8+3.9
2d
+2.6+2.2+0.4+6.8-4.2
3d
+2.0+1.8+0.2+2.3-0.2
4d
+2.2+1.4+0.8+2.3-0.1
5d
+1.0pendingpending+1.1-0.1
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Midcap 150Sector · Biotechnology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 8% to INR594 crore. EBITDA was INR330 crore at a 50.6% margin and profit after tax was INR211 crore at 32.04%. H1 revenue was INR1,012 crore, profit after tax INR331 crore and net cash INR1,534 crore. Anthem has 15 commercial and nine late-stage programs. Specialty Ingredients is targeted at least 20% of year-end sales; Unit 4 spending is near INR1,200 crore over two years, with 1.5x asset turns targeted next year.

Likely market impact

Strong margins and net cash support sentiment, but lumpy demand and customer concentration, with the top 10 at about 80% of sales, are risks.